IL253896B - in mesinesulfonamides that are npc1 inhibitors for the treatment of Niemann-Pick disease and other liposomal storage disorders - Google Patents
in mesinesulfonamides that are npc1 inhibitors for the treatment of Niemann-Pick disease and other liposomal storage disordersInfo
- Publication number
- IL253896B IL253896B IL253896A IL25389617A IL253896B IL 253896 B IL253896 B IL 253896B IL 253896 A IL253896 A IL 253896A IL 25389617 A IL25389617 A IL 25389617A IL 253896 B IL253896 B IL 253896B
- Authority
- IL
- Israel
- Prior art keywords
- neimann
- upregulators
- npc1
- benzenesulfonamide
- lysosomal storage
- Prior art date
Links
- KHBQMWCZKVMBLN-UHFFFAOYSA-N Benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1 KHBQMWCZKVMBLN-UHFFFAOYSA-N 0.000 title 1
- 201000011240 Frontotemporal dementia Diseases 0.000 title 1
- 208000015439 Lysosomal storage disease Diseases 0.000 title 1
- 208000000609 Pick Disease of the Brain Diseases 0.000 title 1
- 208000024571 Pick disease Diseases 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
- C07C311/21—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/335—Radicals substituted by nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
- C07D213/46—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562114840P | 2015-02-11 | 2015-02-11 | |
| PCT/US2016/017504 WO2016130774A1 (en) | 2015-02-11 | 2016-02-11 | Benzenesulfonamide upregulators of npc1 for neimann-pick disease and other lysosomal storage disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL253896A0 IL253896A0 (en) | 2017-10-31 |
| IL253896B true IL253896B (en) | 2019-09-26 |
Family
ID=56614815
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL253896A IL253896B (en) | 2015-02-11 | 2017-08-08 | in mesinesulfonamides that are npc1 inhibitors for the treatment of Niemann-Pick disease and other liposomal storage disorders |
| IL26881119A IL268811A (en) | 2015-02-11 | 2019-08-21 | Benzenesulfonamides that are NPC1 inhibitors for the treatment of Niemann-Pick disease and other leprosy storage disorders |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL26881119A IL268811A (en) | 2015-02-11 | 2019-08-21 | Benzenesulfonamides that are NPC1 inhibitors for the treatment of Niemann-Pick disease and other leprosy storage disorders |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US10239830B2 (cg-RX-API-DMAC10.html) |
| EP (1) | EP3256116B1 (cg-RX-API-DMAC10.html) |
| JP (1) | JP6887389B2 (cg-RX-API-DMAC10.html) |
| CN (1) | CN107949380B (cg-RX-API-DMAC10.html) |
| AU (1) | AU2016219231B2 (cg-RX-API-DMAC10.html) |
| CA (1) | CA2976449C (cg-RX-API-DMAC10.html) |
| IL (2) | IL253896B (cg-RX-API-DMAC10.html) |
| WO (1) | WO2016130774A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111289749B (zh) * | 2018-12-10 | 2023-04-14 | 北京蛋白质组研究中心 | C型1类尼曼-匹克蛋白检测物在制备筛查肝细胞癌产品中的应用 |
| WO2021150695A1 (en) * | 2020-01-22 | 2021-07-29 | Icahn School Of Medicine At Mount Sinai | Constrained n-substituted tetrahydrobenzoazepine sulfonamides as anticancer and neuroprotective agents |
| WO2022159566A1 (en) | 2021-01-21 | 2022-07-28 | Icahn School Of Medicine At Mount Sinai | Benzenesulfonamide agonists of trap1 for treating organ fibrosis |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6177447B1 (en) * | 1996-07-15 | 2001-01-23 | Universiteit Van Amsterdam | Deoxynojirimycin derivatives and their uses as glucosylceramidase inhibitors |
| DE69926148D1 (en) * | 1998-11-09 | 2005-08-18 | Black James Foundation | Gastrin und cholecystokinin rezeptor ligande |
| AU2003301443A1 (en) * | 2002-10-18 | 2004-05-04 | E.I. Du Pont De Nemours And Company | Azolecarboxamide herbicides |
| CA2881078C (en) | 2004-06-24 | 2018-10-02 | Vertex Pharmaceuticals Incorporated | Modulators of atp-binding cassette transporters |
| US8354427B2 (en) | 2004-06-24 | 2013-01-15 | Vertex Pharmaceutical Incorporated | Modulators of ATP-binding cassette transporters |
| MX2008013194A (es) | 2006-04-11 | 2008-12-01 | Vertex Pharma | Composiciones utiles como inhibidores de canales de sodio regulados por voltaje. |
| US9732067B2 (en) * | 2012-06-20 | 2017-08-15 | University Of Kansas | Compounds and methods for activating the apoptotic arm of the unfolded protein response |
| CA2880880C (en) * | 2012-08-03 | 2021-01-26 | John Mckew | Cyclodextrin for the treatment of lysosomal storage diseases |
| US20140128352A1 (en) | 2012-09-20 | 2014-05-08 | Buck Institute For Research On Aging | Compounds and methods for modulating mitochondrial metabolism and reactive oxygen species production |
| EP2823816A1 (en) | 2013-07-09 | 2015-01-14 | Tragex Pharma | Inhibitors of Neuropilin and use thereof for the treatment of Neuropilin-related diseases |
-
2016
- 2016-02-11 US US15/549,743 patent/US10239830B2/en active Active
- 2016-02-11 JP JP2017560888A patent/JP6887389B2/ja active Active
- 2016-02-11 WO PCT/US2016/017504 patent/WO2016130774A1/en not_active Ceased
- 2016-02-11 CN CN201680020467.XA patent/CN107949380B/zh active Active
- 2016-02-11 EP EP16749864.1A patent/EP3256116B1/en active Active
- 2016-02-11 AU AU2016219231A patent/AU2016219231B2/en active Active
- 2016-02-11 CA CA2976449A patent/CA2976449C/en active Active
-
2017
- 2017-08-08 IL IL253896A patent/IL253896B/en active IP Right Grant
-
2019
- 2019-08-21 IL IL26881119A patent/IL268811A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2016219231A1 (en) | 2017-09-28 |
| US20180044286A1 (en) | 2018-02-15 |
| CA2976449A1 (en) | 2016-08-18 |
| IL268811A (en) | 2019-10-31 |
| AU2016219231A2 (en) | 2017-09-28 |
| CN107949380A (zh) | 2018-04-20 |
| JP6887389B2 (ja) | 2021-06-16 |
| EP3256116B1 (en) | 2022-08-17 |
| EP3256116A1 (en) | 2017-12-20 |
| CN107949380B (zh) | 2021-07-06 |
| EP3256116A4 (en) | 2018-07-11 |
| WO2016130774A1 (en) | 2016-08-18 |
| JP2018510904A (ja) | 2018-04-19 |
| CA2976449C (en) | 2022-08-09 |
| AU2016219231B2 (en) | 2020-08-20 |
| US10239830B2 (en) | 2019-03-26 |
| IL253896A0 (en) | 2017-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SI3487505T1 (sl) | Dajanje in odmerek diaminofenotiazinov | |
| GB201503615D0 (en) | Generation and use of similar multiple beams | |
| HUE036084T2 (hu) | Buprenorfin dimer és alkalmazása gasztrointesztinális rendellenességek kezelésénél | |
| IL266132B (en) | Pharmaceutical formulations and methods for their preparation | |
| EP3178473C0 (en) | ACID-RESISTANT CAPSULE COVER AND PREPARATION METHOD THEREFOR | |
| PT3380525T (pt) | Formulações farmacêuticas e métodos que as utilizam | |
| ZA201902090B (en) | Combination treatments comprising administration of imidazopyrazinones | |
| IL327244A (en) | Pharmaceutical compositions and uses directed against lysosomal storage disorders | |
| IL247978A0 (en) | Modified sulfamidase and its production | |
| IL257932A (en) | Adapted cytotoxins and their therapeutic uses | |
| TWI563001B (en) | Disintegrin variants and pharmaceutical uses thereof | |
| SG11201604840TA (en) | Prophylactic and/or therapeutic agent for functional gastrointestinal disorders | |
| IL268811A (en) | Benzenesulfonamides that are NPC1 inhibitors for the treatment of Niemann-Pick disease and other leprosy storage disorders | |
| IL257806A (en) | Laxative formulations and manufacture | |
| PL3697392T3 (pl) | Tabletki zawierające tamsulosynę i solifenacynę | |
| GB201419354D0 (en) | Pharmaceutical extracts and uses thereof | |
| AP2017009817A0 (en) | Capsaicinoids and uses thereof as medicaments | |
| GB201612863D0 (en) | Administration and dosage of diaminophenothiazines | |
| GB201511863D0 (en) | Pharmaceutical compositions comprising hexaminolevulnic acid and methods of using the same | |
| GB201401314D0 (en) | Bernard's theory of software and technology |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed |